Liraglutide for weight loss: what TikTok gets right and wrong

What's this video probably claiming?

Based on the hashtags #liraglutida, #miexperienciaconliraglutida, and #procesodeperdidadepeso, this creator is almost certainly sharing a personal weight loss journey using liraglutide, the GLP-1 receptor agonist sold under the brand names Saxenda (for weight management) and Victoza (for type 2 diabetes). These videos typically follow a familiar format: before-and-after framing, weekly injection updates, side effect confessions, and a general tone of "this changed my life." The creator is probably reporting meaningful weight loss, describing appetite suppression as near-magical, and may be comparing liraglutide to semaglutide or tirzepatide. There is also a reasonable chance this video glosses over the dose titration process, understates gastrointestinal side effects, or implies results that were achieved under medical supervision are replicable without it.

What does the science actually show?

Liraglutide at 3.0 mg daily (the Saxenda dose) does produce real, clinically meaningful weight loss, but the numbers are more modest than the semaglutide era has made people expect. The SCALE Obesity and Prediabetes trial (Pi-Sunyer et al., 2015, NEJM) found that liraglutide 3.0 mg produced an average 8.4% body weight reduction over 56 weeks versus 2.8% for placebo. About 63% of participants lost at least 5% of body weight. That is a legitimate result. However, for context, the STEP 1 trial (Wilding et al., 2021, NEJM) showed semaglutide 2.4 mg producing roughly 14.9% weight loss over 68 weeks in a comparable population. Liraglutide requires daily subcutaneous injections versus semaglutide's weekly schedule, and the dropout rates in liraglutide trials due to nausea and GI intolerance have historically been higher. Real-world persistence data from Wharton et al. (2019, Obesity) showed only about 35% of patients were still on liraglutide at 12 months.

Where does the social media noise diverge from clinical reality?

The gap between TikTok liraglutide content and clinical reality is wide in a few specific directions. First, creators almost never address the dose titration schedule: liraglutide is started at 0.6 mg daily and increased by 0.6 mg weekly until reaching 3.0 mg, a process taking four to five weeks. Jumping doses accelerates nausea and increases discontinuation. Second, weight regain after stopping is rarely discussed honestly. Data from Fujioka (2015, Clinical Diabetes and Endocrinology) and subsequent analyses confirm that most patients regain significant weight within months of stopping GLP-1 therapy, liraglutide included. Third, cost and access are skipped entirely. Saxenda lists above $1,300 per month in the US without insurance. Fourth, creators conflate their individual responses with expected outcomes, which is particularly misleading given the wide responder variability documented in clinical trial subgroup analyses.

What should you actually know?

Liraglutide is a legitimate, FDA-approved medication with a real evidence base for weight management. It is not a scam, and personal success stories from creators like this one are not fabricated. But the clinical context matters enormously. The drug works best within a structured program that includes dietary counseling and behavioral support, which is exactly how it was studied in SCALE trials. Liraglutide is also not interchangeable with semaglutide or tirzepatide: different molecules, different receptor binding profiles, different efficacy data, and different side effect burdens. Anyone watching this video and considering liraglutide should speak with a licensed prescriber who can assess cardiovascular history (there is a black box warning for thyroid C-cell tumors in rodents, and personal or family history of MEN2 or medullary thyroid carcinoma is a contraindication). The TikTok version of this medication is cleaner, faster, and easier than the clinical version almost always is.